Subcutaneous Versions of IV Oncology Drugs Can Offer Various Benefits

May 08
May 08, 2025

Multiple oncology drugs that first launched as intravenous (IV) infusions are now available as subcutaneous (SC) injections. The new formulations can provide advantages such as shorter infusion times, which can benefit both patients and crowded infusion suites. But an array of considerations should be taken into account, and not every patient may be a suitable candidate for the therapies.

Among the agents are Roche Group member Genentech USA, Inc.’s Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), Johnson & Johnson Innovative Medicine’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) and Bristol Myers Squibb’s Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Merck & Co., Inc.’s SC Keytruda (pembrolizumab) is awaiting an FDA decision on its approval, which is expected by Sept. 23.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.